LRP6 and plasma cell myeloma: As illustrated in Fig. 3A, we treated both naïve (non‐tumor‐bearing) mice and mice bearing murine 5TGM1 myeloma cells with anti‐LRP6 antibody twice weekly and measured bone structural changes by μCT analysis (Fig. 3B–D).